These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 15599853)

  • 1. Novel therapeutic targets in squamous cell carcinoma of the head and neck.
    Cohen EE
    Semin Oncol; 2004 Dec; 31(6):755-68. PubMed ID: 15599853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simultaneously targeting epidermal growth factor receptor tyrosine kinase and cyclooxygenase-2, an efficient approach to inhibition of squamous cell carcinoma of the head and neck.
    Chen Z; Zhang X; Li M; Wang Z; Wieand HS; Grandis JR; Shin DM
    Clin Cancer Res; 2004 Sep; 10(17):5930-9. PubMed ID: 15355926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination antiangiogenic therapy and radiation in head and neck cancers.
    Hsu HW; Wall NR; Hsueh CT; Kim S; Ferris RL; Chen CS; Mirshahidi S
    Oral Oncol; 2014 Jan; 50(1):19-26. PubMed ID: 24269532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting pathways mediating resistance to anti-EGFR therapy in squamous cell carcinoma of the head and neck.
    Campbell NP; Hensing TA; Bhayani MK; Shaikh AY; Brockstein BE
    Expert Rev Anticancer Ther; 2016 Aug; 16(8):847-58. PubMed ID: 27400139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecularly targeted agents in the treatment of recurrent or metastatic squamous cell carcinomas of the head and neck.
    Le Tourneau C; Chen EX
    Hematol Oncol Clin North Am; 2008 Dec; 22(6):1209-20, ix. PubMed ID: 19010269
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 2-methoxyestradiol inhibits hypoxia-inducible factor 1alpha, tumor growth, and angiogenesis and augments paclitaxel efficacy in head and neck squamous cell carcinoma.
    Ricker JL; Chen Z; Yang XP; Pribluda VS; Swartz GM; Van Waes C
    Clin Cancer Res; 2004 Dec; 10(24):8665-73. PubMed ID: 15623651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiangiogenic hypoxic cytotoxin TX-402 inhibits hypoxia-inducible factor 1 signaling pathway.
    Nagasawa H; Mikamo N; Nakajima Y; Matsumoto H; Uto Y; Hori H
    Anticancer Res; 2003; 23(6a):4427-34. PubMed ID: 14666730
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overview of Current Treatment Options and Investigational Targeted Therapies for Locally Advanced Squamous Cell Carcinoma of the Head and Neck.
    Zibelman M; Mehra R
    Am J Clin Oncol; 2016 Aug; 39(4):396-406. PubMed ID: 26967327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular-targeted therapies in the treatment of squamous cell carcinomas of the head and neck.
    Le Tourneau C; Siu LL
    Curr Opin Oncol; 2008 May; 20(3):256-63. PubMed ID: 18391623
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro study of normoxic epidermal growth factor receptor-induced hypoxia-inducible factor-1-alpha, vascular endothelial growth factor, and BNIP3 expression in head and neck squamous cell carcinoma cell lines: Implications for anti-epidermal growth factor receptor therapy.
    Secades P; de Santa-María IS; Merlo A; Suarez C; Chiara MD
    Head Neck; 2015 Aug; 37(8):1150-62. PubMed ID: 24798801
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Chemoradiotherapy in head and neck squamous cell carcinoma: focus on targeted therapies].
    Bozec A; Thariat J; Bensadoun RJ; Milano G
    Cancer Radiother; 2008 Jan; 12(1):14-24. PubMed ID: 18248834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecularly targeted agents and immunotherapy for the treatment of head and neck squamous cell cancer (HNSCC).
    Azoury SC; Gilmore RC; Shukla V
    Discov Med; 2016 Jun; 21(118):507-16. PubMed ID: 27448787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Incorporation of molecularly targeted agents in the primary treatment of squamous cell carcinomas of the head and neck.
    Bernier J
    Hematol Oncol Clin North Am; 2008 Dec; 22(6):1193-208, ix. PubMed ID: 19010268
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of and therapeutic approaches for overcoming resistance to epidermal growth factor receptor (EGFR)-targeted therapy in squamous cell carcinoma of the head and neck (SCCHN).
    Price KA; Cohen EE
    Oral Oncol; 2015 May; 51(5):399-408. PubMed ID: 25725588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel treatments for head and neck squamous cell carcinoma: preclinical identification and clinical investigation.
    Bowles DW; McDermott JD; Jimeno A
    Future Oncol; 2014 May; 10(6):1065-80. PubMed ID: 24941990
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Head and neck squamous cell carcinoma: new translational therapies.
    Prince A; Aguirre-Ghizo J; Genden E; Posner M; Sikora A
    Mt Sinai J Med; 2010; 77(6):684-99. PubMed ID: 21105129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular targeted therapies in the management of head and neck squamous cell carcinoma: recent developments and perspectives.
    Bozec A; Peyrade F; Milano G
    Anticancer Agents Med Chem; 2013 Mar; 13(3):389-402. PubMed ID: 23092267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeting the Tumor Environment in Squamous Cell Carcinoma of the Head and Neck.
    Schmitz S; Machiels JP
    Curr Treat Options Oncol; 2016 Jul; 17(7):37. PubMed ID: 27262711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting EGFR-PI3K-AKT-mTOR signaling enhances radiosensitivity in head and neck squamous cell carcinoma.
    Horn D; Hess J; Freier K; Hoffmann J; Freudlsperger C
    Expert Opin Ther Targets; 2015 Jun; 19(6):795-805. PubMed ID: 25652792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The epidermal growth factor receptor signaling network in head and neck carcinogenesis and implications for targeted therapy.
    Pomerantz RG; Grandis JR
    Semin Oncol; 2004 Dec; 31(6):734-43. PubMed ID: 15599851
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.